frame-graph02ttt01Overall1.800.20.40.60.811.21.41.6PlaceboXyzalP<0.001Improvement in RQLQQoL_Chart1_All_m[1]OverallPlaceboXyzalP<0.0011.800.20.40.60.811.21.41.6Improvement in RQLQ37%improvementvs placebo (P<0.001)Vector Smart ObjectNasalSymptomsEyeSymptoms**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]*P<0.001;P<0.05PlaceboXyzalNasalSymptomsEyeSymptoms**1.800.20.40.60.811.21.41.6Improvement in RQLQVector Smart Object2ActivitiesSleepPracticalProblemsEmotional**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]ActivitiesSleepPracticalProblemsEmotional**1.800.20.40.60.811.21.41.6*P<0.001;P<0.05PlaceboXyzalImprovement in RQLQttt02Improvement in WPAI-AS Scores20181614121086420Patient Xperience20181614121086420ctaObject1LevocetirizineXyzalvs.LevocetirizineXyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgvs.Xyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgLevocetirizinesymptom-xpert-graph00-desktop-50-40-30-20-100Xyzal(n=240)Xyzal(n=236)!"!#!$!"#$()*+,-./,01-50-40-30-20-100Percent Reduction in MSCS with XyzalXyzal(n=240)Xyzal(n=236)46%reduction vs 11% placebo (n=93) (P<0.001)34% reduction vs 18% placebo (n=95) (P<0.001)Hour 1Hour 24Week 8Mean T4SS Change from BaselineWeek 10-0.5-1-1.5-2-2.5-3-3.5-4PlaceboXyzalVector Smart Object4PlaceboXyzalWeek 1Week 80-0.5-1-1.5-2-2.5-3-3.5-486%Reductionvs placebo(P<0.001)47%Reductionvs placebo(P<0.001)Mean T4SS Change from Baseline0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4symptom-xpert-graph02-desktopWeek 100.20.40.60.81.06 MonthsMean T5SS Change from BaselineXyzalPlacebo6 MonthsWeek 1PlaceboXyzal00.20.40.60.81.06 MonthsMean T5SS Change from BaselineWeek 16 Months00.20.40.60.81.0PlaceboXyzalMean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineSignificant Reduction in Symptoms14121086420-2-101 25 26 27 28Mean Score (MSCS)24PlaceboXyzal 5 mg (P<0.001)Hours After Drug IntakeSignificant Reduction in Symptoms

For U.S. Healthcare Professionals Only

QOL

Real Relief for Improved
Quality of Life

Significant improvement in overall QOL and all composite scores1:

reduction (improvement) from baseline in Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ) scores

With Xyzal OTC, patients saw improvement in aspects of their life  
impacted by their allergy symptoms1

Footnotes & References
x
  • A randomized, double-blind, placebo-controlled, parallel-group study of 5 mg/day vs placebo for 14 days in 580 US adults (aged 18-65 years) with seasonal allergic rhinitis evaluated improvement of symptoms and health-related quality of life.
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)=a disease-specific, validated, reproducible instrument for evaluating health-related QOL on the basis of how symptoms and treatments affect each patient’s physical, social, and emotional well-being.
  • Reference: 1. Segall N, Gawchik S, Georges G, Haeusler J-MC. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol. 2010;104(3):259-267.

Symptom relief that doesn't get in the way
of patients' work

Significantly more patients reported less impairment
and missed less
time from work due to allergies1:

WPAI-AS questionnaire (adjusted mean between-group difference of –4.44%, P<0.05)

Improvement in
WPAI-AS Scores

n=214
n=223

Less impairment
at work due
to
allergies

Improvement in
WPAI-AS Scores

n=214
n=225

Less work
missed
due
to allergies

Footnotes & References
x
  • A randomized, double-blind, placebo-controlled, parallel-group study of 5 mg/day vs placebo for 14 days in 580 US adults (aged 18-65 years) with seasonal allergic rhinitis evaluated improvement of symptoms and health-related quality of life.
  • WPAI-AS=Work Productivity and Activity Impairment–Allergy Specific (WPAI-AS) questionnaire measures performance based on 3 work-related components: work time missed, impairment while working, and overall work impairment.
  • Reference: 1. Segall N, Gawchik S, Georges G, Haeusler J-MC. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol. 2010;104(3):259-267.

Patient satisfaction was greater with Xyzal vs Zyrtec

Higher global satisfaction scores with Xyzal vs Zyrtec1:

evaluated in 10 half-hourly measurements following the first dose

5

Points Greater Satisfaction

among patients taking Xyzal vs those taking Zyrtec, evaluated by patients on a VAS ranging from 0 to 100 cm

Global satisfaction score (mean VAS): 70.2 with Xyzal vs 65.2 with Zyrtec (P=0.038) and 41.2
with placebo.1

Footnotes & References
x
  • A double-blind, double-dummy, parallel-group, randomized, placebo-controlled study (N=563) comparing the efficacy of a single dose of levocetirizine 5 mg (n=236) vs cetirizine 10 mg (n=233) vs placebo (n=94). Primary efficacy variable was mean change from baseline in major symptoms complex (MSC).
  • Global satisfaction score (mean visual analog scale)=evaluated by the willingness of the subjects to take the medication during the next pollen season.

  • Reference: 1. Data on file, sanofi-aventis U.S. LLC.

More patients wanted to stay with Xyzal vs Zyrtec
for the next allergy season

Significantly more patients taking Xyzal wanted to 
continue treatment1:

based on global satisfaction, indicated by patients’ willingness to continue treatment during the next pollen season, evaluated in 10 half-hourly measurements following the first dose

63%

with Zyrtec
VS

72%

with Xyzal

(P=0.039)

Footnotes & References
x
  • A double-blind, double-dummy, parallel-group, randomized, placebo-controlled study (N=563) comparing the efficacy of a single dose of levocetirizine 5 mg (n=236) vs cetirizine 10 mg (n=233) vs placebo (n=94). Primary efficacy variable was mean change from baseline in major symptoms complex (MSC).
  • Global satisfaction score (mean visual analog scale)=evaluated by the willingness of the subjects to take the medication during the next pollen season.

  • Reference: 1. Data on file, sanofi-aventis U.S. LLC.